ClinicalTrials.gg
CompletedNCT05514535Updated May 11, 2026Results posted

A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)

A Phase 3 interventional study of Semaglutide and Insuline glargine U100 (reduced) in Diabetes Mellitus, Type 2 and Obesity, sponsored by Novo Nordisk A/S. Completed at 239 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-11.

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
573
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 163 studies testing semaglutide in Diabetes Mellitus, Type 2 — 35 open to participants now, 45 under way, 9 of them phase 3. Semaglutide · Diabetes Mellitus, Type 2.

Enrollment
32nd of 163
573 · median 104
Started
2022
with 17 others
Phase 3
57 of 163
7 open now
Registered
105th of 163
by date
Lead sponsor
89 of 163
Novo Nordisk A/S

Among the 163 studies testing semaglutide in Diabetes Mellitus, Type 2, this one is the 32nd largest by enrollment, is one of 18 that started in 2022, is one of 57 in phase 3, and was the 105th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

35 of the 163 studies testing semaglutide in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:

30 more — sign in →

By country, each count listing its studies:

All 35 open studies →

About semaglutide

Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 163 studies testing semaglutide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This study compares semaglutide, together with a lower dose of insulin glargine, to a higher dose of insulin glargine in participants with type 2 diabetes. The study looks at how well the study medicines control blood glucose levels. Participants will either get semaglutide together with a lower dose of insulin glargine or a higher dose of insulin glargine. The study will last for about 47 weeks (approximately 11 months). Participants will have 9 clinic visits, 15 phone/video calls and 1 home visit. Participants will be asked to wear a sensor that measures their blood sugar all the time in 2 periods of 10 days during the study.

03

Conditions studied

  • Diabetes Mellitus, Type 2
  • Obesity
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with Type 2 Diabetes Mellitus (T2D) mellitus greater than or equal to (>=) 180 days before screening.
  • (HbA1c) of 7-10 percentage [(53-86 millimoles per mole (mmol/mol)] (both inclusive) as assessed by central laboratory on the day of screening.
  • (BMI) greater than or equal to (>=) 25 kilograms per meter square (kg/m\^2) on the day of screening.
  • Stable daily dose(s) greater than or equal to (>=) 90 days before screening of any of the following anti-diabetic drugs or combination regimens:
  • Any metformin formulations greater than or equal to (>=) 1500 milligrams (mg) or maximum tolerated or effective dose.
  • Any metformin combination formulation greater than or equal to (>=) 1500 mg or maximum tolerated or effective dose.

The treatment can be with or without sodium glucose cotransporter 2 (SGLT-2) inhibitors.

  • Treated with a once daily basal insulin (e.g. insulin glargine Unit 100 or U300, neutral protamine hagedorn (NPH) insulin, insulin detemir, insulin degludec) less than or equal to (\<=) 40 units/day (U/day) for greater than or equal to (>=) 90 days before screening. Short-term bolus insulin treatment for a maximum of 14 days before screening is allowed.

Exclusion criteria

Exclusion Criteria:

  • Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within the past 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
  • Potentially missed diagnosis of Type 1 diabetes (T1D) or latent diabetes in adults (LADA) verified by C-peptide less than 0.26 nanomoles per litre (nmol/L) (or 260 picomoles per liter [pmol/L] [0.78 nanograms per millilitre {ng/mL}]) or antibodies to glutamic acid decarboxylase (anti-GAD) greater than 5 units/millilitre, as measured by the central laboratory at screening.
  • Presence or history of pancreatitis (acute or chronic).
  • Renal impairment measured as estimated (eGFR) value of less than 30 millilitre per minute per 1.73 meter square at screening as defined by Kidney Disease: Improving Global Outcomes (KDIGO) 2012 classification.
  • Any episodes of diabetic ketoacidosis within 90 days before screening.
  • Known hypoglycaemic unawareness as indicated by the investigator according to Clarke's questionnaire question 8.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
573 participants (actual)

Study arms

  • Experimental
    Insuline glargine U100 (reduced) + semaglutide

    Participants will initially receive 0.25 milligrams (mg) once-weekly semaglutide subcutaneously (s.c.) and the dose will be gradually escalated to 2 mg as an add-on to dose-reduced insulin glargine s.c. given once-daily. Insulin glargine U100 will be reduced by 10 U at the initiation of semaglutide and then again at each semaglutide dose escalation. Insulin glargine dose will be adjusted based on the mean of three pre-breakfast self-measured plasma glucose (SMPG) values (target SMPG: 4.4-7.2 millimoles per litre (mmol/L)).

    Drug: Semaglutide · Drug: Insuline glargine U100 (reduced)

  • Active comparator
    Insuline glargine U100 (titrated)

    Participants will receive titrated insuline glargine U100 s.c. once-daily. Insulin glargine U100 dose will be adjusted based on the mean of three pre-breakfast SMPG values (target SMPG: 4.4-7.2 mmol/L).

    Drug: Insuline glargine U100 (titrated)

Interventions

  • Participants will receive once-weekly semaglutide s.c. for 40 weeks. Semaglutide 0.25 mg will be given at week 0 and then the dose will be escalated at weeks 4, 8 and 12 to 0.5 mg, 1 mg, 2 mg respectively.

  • DrugInsuline glargine U100 (reduced)

    Participants will receive insulin glargine U100 s.c. once-daily. Insulin glargine dose will be reduced by 10 U at initiation of semaglutide and then again at each semaglutide dose escalation up to 40 weeks. The dose will be adjusted based on the mean of three pre-breakfast SMPG values (target SMPG: 4.4-7.2 mmol/L).

  • DrugInsuline glargine U100 (titrated)

    Participants will receive titrated insulin glargine U100 s.c. once-daily up to 40 weeks. The dose will be adjusted based on the mean of three pre-breakfast SMPG values (target SMPG: 4.4-7.2 mmol/L).

06

What researchers measure

Primary outcomes

  1. Change in Glycated Haemoglobin (HbA1c) [Noninferiority]

    Change in HbA1c (Noninferiority) from baseline (Week 0) to end of treatment (Week 40) were reported. Here noninferiority was assessed based on the clinically acceptable margin of 0.3%-point for the mean treatment difference in HbA1c.

    Time frame: From baseline (week 0) to end of treatment (week 40)

Secondary outcomes

  1. Change in Body Weight

    Change in body weight from baseline (Week 0) to end of treatment (Week 40) were reported. Body weight was measured in unit 'Kilogram (kg)'.

    Time frame: From baseline (week 0) to end of treatment (week 40)

  2. Percentage Change in Daily Insulin Dose

    Percentage change in daily insulin dose from baseline (Week 0) to end of treatment (Week 40) were reported. Percentage change from baseline to week 40 in insulin dose (%) was calculated as: (\[insulin dose at week 40\] - \[insulin dose at baseline\]) / \[insulin dose at baseline\] × 100.

    Time frame: From baseline (week 0) to end of treatment (week 40)

  3. Change in Glycated Haemoglobin (HbA1c ) [Superiority]

    Change in HbA1c (Superiority) from baseline (Week 0) to end of treatment (Week 40) were reported.

    Time frame: From baseline (week 0) to end of treatment (week 40)

  4. Score of Diabetes Treatment Satisfaction Questionnaire - Change Version (DTSQc)

    Score of Diabetes Treatment Satisfaction Questionnaire - change version (DTSQc) at end of treatment (week 40) were reported. The DTSQc provided a measure of how satisfied participants were with their current diabetes treatment compared with previous treatment. It consisted of 8 questions, which were to be answered on a Likert scale from -3 to +3 (-3 = much less satisfied now to +3 = much more satisfied now), with 0 (midpoint) representing no change. Out of 8 questions, 6 questions related to treatment satisfaction were summed to produce a total score. The DTSQc total treatment satisfaction score ranged from -18 to +18, with higher scores associated with greater treatment satisfaction.

    Time frame: At end of treatment (week 40)

  5. Number of Participants Achieving Insulin Dose = 0 Units/mL (U)

    Number of participants achieving Insulin dose = 0 U at the end of treatment (Week 40) were reported.

    Time frame: At end of treatment (week 40)

  6. Number of Participants Achieving Insulin Dose Reduced From Baseline by at Least 50%

    Number of participants achieving Insulin dose reduced from baseline by at least 50% by end pf treatment (Week 40) were reported.

    Time frame: At end of treatment (week 40)

  7. Number of Participants Achieving HbA1c Less Than (<) 7%

    Number of participants achieving HbA1c \< 7% at the end of treatment (Week 40) were reported.

    Time frame: At end of treatment (week 40)

  8. Number of Severe Hypoglycaemic Episodes (Level 3)

    Number of severe hypoglycaemic episodes (level 3) from baseline (week 0) to end of treatment (week 40) were reported. Severe hypoglycaemia (level 3) was defined as hypoglycaemia with severe cognitive impairment requiring external assistance for recovery.

    Time frame: From baseline (week 0) to end of treatment (week 40)

  9. Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (<3.0 mmol/L (54 mg/dL), Confirmed by Blood Glucose (BG) Meter)

    Number of clinically significant hypoglycaemic episodes (level 2) (\<3.0 mmol/L (54 mg/dL), confirmed by BG meter) from baseline (week 0) to end of treatment (week 40) were reported. Clinically significant hypoglycaemia (level 2) was defined as plasma glucose value of less than (\<) 3.0 mmol/L (54 mg/dL) confirmed by BG meter.

    Time frame: From baseline (week 0) to end of treatment (week 40)

  10. Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (<3.0 mmol/L (54 mg/dL), Confirmed by BG Meter) or Severe Hypoglycaemic Episodes (Level 3)

    Number of clinically significant hypoglycaemic episodes (level 2) (\<3.0 mmol/L (54 mg/dL), confirmed by BG meter) or severe hypoglycaemic episodes (level 3) from baseline (week 0) to end of treatment (week 40) were reported. Clinically significant hypoglycaemia (level 2) was defined as plasma glucose value of less than (\<) 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3) was defined as hypoglycaemia with severe cognitive impairment requiring external assistance for recovery.

    Time frame: From baseline (week 0) to end of treatment (week 40)

  11. Number of Participants Achieving HbA1c Reduced From Baseline by at Least 0.3%-Points and Insulin Dose Reduced From Baseline, No Hypoglycaemic Episodes (< 3.9 mmol/L (70 mg/dL) Confirmed by BG Meter) and No Weight Gain

    Number of Participants achieving HbA1c reduced from baseline by at least 0.3%-points and Insulin dose reduced from baseline, No hypoglycaemic episodes (\< 3.9 mmol/L (70 mg/dL) confirmed by BG meter) and No weight gain at the end of treatment (Week 40) were reported.

    Time frame: At end of treatment (week 40)

  12. Change in Score of Diabetes Treatment Satisfaction Questionnaire - Status Version (DTSQs)

    Score of Diabetes Treatment Satisfaction Questionnaire - status version (DTSQs) at end of treatment (week 40) were reported. The status version measures a patient's current satisfaction with treatment using a 0-6 scale for each item; higher scores indicate greater satisfaction with the present treatment (absolute/status level). The DTSQs total treatment satisfaction score ranged from 0 to 36, with higher scores associated with greater treatment satisfaction.

    Time frame: From baseline (week 0) to end of treatment (week 40)

  13. Change in Score of Short Form 36 Version 2 (SF-36 v2)

    Change in SF-36 physical and mental component from baseline (week 0) to end of treatment (Week 40) were presented. SF-36 is self-administered questionnaire that measures each of following 8 health domains: physical functioning, role limitations due to physical problems (role-physical), social functioning, bodily pain, mental health, role limitations due to emotional problems (role-emotional), vitality, and general health perception. There are also 2 component scores derived from the 8 subscale scores: mental component summary and physical component summary. Physical component summary contains physical functioning, role-physical, bodily pain and general health and mental component summary contain vitality, social functioning, role-emotional and mental health. Each SF-36 domain and component summary score ranges from 0 to 100, higher scores reflect better participant health status. A positive change score indicates an improvement since baseline.

    Time frame: From baseline (week 0) to end of treatment (week 40)

07

Results

Posted May 11, 2026

Participant flow

The study was conducted at 140 sites that recruited participants in 9 countries.

Participant flow — Overall Study
MilestoneInsuline Glargine U100 (Reduced) + SemaglutideInsuline Glargine U100 (Titrated)
Started288285
Safety analysis set (sas)288284
Full analysis set (fas)288285
Completed283275
Not completed510
Withdrew: Death11
Withdrew: Physician decision12
Withdrew: Lost to follow-up22
Withdrew: Withdrawal by subject15

Outcome measures

PrimaryChange in Glycated Haemoglobin (HbA1c) [Noninferiority]

Change in HbA1c (Noninferiority) from baseline (Week 0) to end of treatment (Week 40) were reported. Here noninferiority was assessed based on the clinically acceptable margin of 0.3%-point for the mean treatment difference in HbA1c.

Time frame:
From baseline (week 0) to end of treatment (week 40)
Reported as:
Mean · Percentage point of HbA1c
Change in Glycated Haemoglobin (HbA1c) [Noninferiority]
Percentage point of HbA1cInsuline Glargine U100 (Reduced) + SemaglutideInsuline Glargine U100 (Titrated)
Change in Glycated Haemoglobin (HbA1c) [Noninferiority]-1.37 ± 0.84-0.65 ± 0.92
SecondaryChange in Body Weight

Change in body weight from baseline (Week 0) to end of treatment (Week 40) were reported. Body weight was measured in unit 'Kilogram (kg)'.

Time frame:
From baseline (week 0) to end of treatment (week 40)
Reported as:
Mean · Kilograms
Change in Body Weight
KilogramsInsuline Glargine U100 (Reduced) + SemaglutideInsuline Glargine U100 (Titrated)
Change in Body Weight-7.97 ± 5.620.39 ± 4.08
SecondaryPercentage Change in Daily Insulin Dose

Percentage change in daily insulin dose from baseline (Week 0) to end of treatment (Week 40) were reported. Percentage change from baseline to week 40 in insulin dose (%) was calculated as: (\[insulin dose at week 40\] - \[insulin dose at baseline\]) / \[insulin dose at baseline\] × 100.

Time frame:
From baseline (week 0) to end of treatment (week 40)
Reported as:
Mean · Percentage change of daily insulin dose
Percentage Change in Daily Insulin Dose
Percentage change of daily insulin doseInsuline Glargine U100 (Reduced) + SemaglutideInsuline Glargine U100 (Titrated)
Percentage Change in Daily Insulin Dose-15.11 ± 87.25103.42 ± 142.38
SecondaryChange in Glycated Haemoglobin (HbA1c ) [Superiority]

Change in HbA1c (Superiority) from baseline (Week 0) to end of treatment (Week 40) were reported.

Time frame:
From baseline (week 0) to end of treatment (week 40)
Reported as:
Mean · Percentage-point of HbA1c
Change in Glycated Haemoglobin (HbA1c ) [Superiority]
Percentage-point of HbA1cInsuline Glargine U100 (Reduced) + SemaglutideInsuline Glargine U100 (Titrated)
Change in Glycated Haemoglobin (HbA1c ) [Superiority]-1.37 ± 0.84-0.65 ± 0.92
SecondaryScore of Diabetes Treatment Satisfaction Questionnaire - Change Version (DTSQc)

Score of Diabetes Treatment Satisfaction Questionnaire - change version (DTSQc) at end of treatment (week 40) were reported. The DTSQc provided a measure of how satisfied participants were with their current diabetes treatment compared with previous treatment. It consisted of 8 questions, which were to be answered on a Likert scale from -3 to +3 (-3 = much less satisfied now to +3 = much more satisfied now), with 0 (midpoint) representing no change. Out of 8 questions, 6 questions related to treatment satisfaction were summed to produce a total score. The DTSQc total treatment satisfaction score ranged from -18 to +18, with higher scores associated with greater treatment satisfaction.

Time frame:
At end of treatment (week 40)
Reported as:
Mean · Score on a scale
Score of Diabetes Treatment Satisfaction Questionnaire - Change Version (DTSQc)
Score on a scaleInsuline Glargine U100 (Reduced) + SemaglutideInsuline Glargine U100 (Titrated)
Score of Diabetes Treatment Satisfaction Questionnaire - Change Version (DTSQc)14.69 ± 4.6512.11 ± 6.84
SecondaryNumber of Participants Achieving Insulin Dose = 0 Units/mL (U)

Number of participants achieving Insulin dose = 0 U at the end of treatment (Week 40) were reported.

Time frame:
At end of treatment (week 40)
Reported as:
Count of participants · Participants
Number of Participants Achieving Insulin Dose = 0 Units/mL (U)
ParticipantsInsuline Glargine U100 (Reduced) + SemaglutideInsuline Glargine U100 (Titrated)
Number of Participants Achieving Insulin Dose = 0 Units/mL (U)370
SecondaryNumber of Participants Achieving Insulin Dose Reduced From Baseline by at Least 50%

Number of participants achieving Insulin dose reduced from baseline by at least 50% by end pf treatment (Week 40) were reported.

Time frame:
At end of treatment (week 40)
Reported as:
Count of participants · Participants
Number of Participants Achieving Insulin Dose Reduced From Baseline by at Least 50%
ParticipantsInsuline Glargine U100 (Reduced) + SemaglutideInsuline Glargine U100 (Titrated)
Number of Participants Achieving Insulin Dose Reduced From Baseline by at Least 50%1032
SecondaryNumber of Participants Achieving HbA1c Less Than (<) 7%

Number of participants achieving HbA1c \< 7% at the end of treatment (Week 40) were reported.

Time frame:
At end of treatment (week 40)
Reported as:
Count of participants · Participants
Number of Participants Achieving HbA1c Less Than (<) 7%
ParticipantsInsuline Glargine U100 (Reduced) + SemaglutideInsuline Glargine U100 (Titrated)
Number of Participants Achieving HbA1c Less Than (<) 7%224111
SecondaryNumber of Severe Hypoglycaemic Episodes (Level 3)

Number of severe hypoglycaemic episodes (level 3) from baseline (week 0) to end of treatment (week 40) were reported. Severe hypoglycaemia (level 3) was defined as hypoglycaemia with severe cognitive impairment requiring external assistance for recovery.

Time frame:
From baseline (week 0) to end of treatment (week 40)
Reported as:
Number · Episodes
Number of Severe Hypoglycaemic Episodes (Level 3)
EpisodesInsuline Glargine U100 (Reduced) + SemaglutideInsuline Glargine U100 (Titrated)
Number of Severe Hypoglycaemic Episodes (Level 3)614
SecondaryNumber of Clinically Significant Hypoglycaemic Episodes (Level 2) (<3.0 mmol/L (54 mg/dL), Confirmed by Blood Glucose (BG) Meter)

Number of clinically significant hypoglycaemic episodes (level 2) (\<3.0 mmol/L (54 mg/dL), confirmed by BG meter) from baseline (week 0) to end of treatment (week 40) were reported. Clinically significant hypoglycaemia (level 2) was defined as plasma glucose value of less than (\<) 3.0 mmol/L (54 mg/dL) confirmed by BG meter.

Time frame:
From baseline (week 0) to end of treatment (week 40)
Reported as:
Number · Episodes
Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (<3.0 mmol/L (54 mg/dL), Confirmed by Blood Glucose (BG) Meter)
EpisodesInsuline Glargine U100 (Reduced) + SemaglutideInsuline Glargine U100 (Titrated)
Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (<3.0 mmol/L (54 mg/dL), Confirmed by Blood Glucose (BG) Meter)1632
SecondaryNumber of Clinically Significant Hypoglycaemic Episodes (Level 2) (<3.0 mmol/L (54 mg/dL), Confirmed by BG Meter) or Severe Hypoglycaemic Episodes (Level 3)

Number of clinically significant hypoglycaemic episodes (level 2) (\<3.0 mmol/L (54 mg/dL), confirmed by BG meter) or severe hypoglycaemic episodes (level 3) from baseline (week 0) to end of treatment (week 40) were reported. Clinically significant hypoglycaemia (level 2) was defined as plasma glucose value of less than (\<) 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3) was defined as hypoglycaemia with severe cognitive impairment requiring external assistance for recovery.

Time frame:
From baseline (week 0) to end of treatment (week 40)
Reported as:
Number · Episodes
Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (<3.0 mmol/L (54 mg/dL), Confirmed by BG Meter) or Severe Hypoglycaemic Episodes (Level 3)
EpisodesInsuline Glargine U100 (Reduced) + SemaglutideInsuline Glargine U100 (Titrated)
Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (<3.0 mmol/L (54 mg/dL), Confirmed by BG Meter) or Severe Hypoglycaemic Episodes (Level 3)2246
SecondaryNumber of Participants Achieving HbA1c Reduced From Baseline by at Least 0.3%-Points and Insulin Dose Reduced From Baseline, No Hypoglycaemic Episodes (< 3.9 mmol/L (70 mg/dL) Confirmed by BG Meter) and No Weight Gain

Number of Participants achieving HbA1c reduced from baseline by at least 0.3%-points and Insulin dose reduced from baseline, No hypoglycaemic episodes (\< 3.9 mmol/L (70 mg/dL) confirmed by BG meter) and No weight gain at the end of treatment (Week 40) were reported.

Time frame:
At end of treatment (week 40)
Reported as:
Count of participants · Participants
Number of Participants Achieving HbA1c Reduced From Baseline by at Least 0.3%-Points and Insulin Dose Reduced From Baseline, No Hypoglycaemic Episodes (< 3.9 mmol/L (70 mg/dL) Confirmed by BG Meter) and No Weight Gain
ParticipantsInsuline Glargine U100 (Reduced) + SemaglutideInsuline Glargine U100 (Titrated)
Number of Participants Achieving HbA1c Reduced From Baseline by at Least 0.3%-Points and Insulin Dose Reduced From Baseline, No Hypoglycaemic Episodes (< 3.9 mmol/L (70 mg/dL) Confirmed by BG Meter) and No Weight Gain1386
SecondaryChange in Score of Diabetes Treatment Satisfaction Questionnaire - Status Version (DTSQs)

Score of Diabetes Treatment Satisfaction Questionnaire - status version (DTSQs) at end of treatment (week 40) were reported. The status version measures a patient's current satisfaction with treatment using a 0-6 scale for each item; higher scores indicate greater satisfaction with the present treatment (absolute/status level). The DTSQs total treatment satisfaction score ranged from 0 to 36, with higher scores associated with greater treatment satisfaction.

Time frame:
From baseline (week 0) to end of treatment (week 40)
Reported as:
Mean · Score on scale
Change in Score of Diabetes Treatment Satisfaction Questionnaire - Status Version (DTSQs)
Score on scaleInsuline Glargine U100 (Reduced) + SemaglutideInsuline Glargine U100 (Titrated)
Change in Score of Diabetes Treatment Satisfaction Questionnaire - Status Version (DTSQs)4.56 ± 7.042.17 ± 7.04
SecondaryChange in Score of Short Form 36 Version 2 (SF-36 v2)

Change in SF-36 physical and mental component from baseline (week 0) to end of treatment (Week 40) were presented. SF-36 is self-administered questionnaire that measures each of following 8 health domains: physical functioning, role limitations due to physical problems (role-physical), social functioning, bodily pain, mental health, role limitations due to emotional problems (role-emotional), vitality, and general health perception. There are also 2 component scores derived from the 8 subscale scores: mental component summary and physical component summary. Physical component summary contains physical functioning, role-physical, bodily pain and general health and mental component summary contain vitality, social functioning, role-emotional and mental health. Each SF-36 domain and component summary score ranges from 0 to 100, higher scores reflect better participant health status. A positive change score indicates an improvement since baseline.

Time frame:
From baseline (week 0) to end of treatment (week 40)
Reported as:
Mean · Score on a scale
Change in Score of Short Form 36 Version 2 (SF-36 v2)
Score on a scaleInsuline Glargine U100 (Reduced) + SemaglutideInsuline Glargine U100 (Titrated)
Physical Component Score3.18 ± 7.470.12 ± 6.67
Mental Component Score1.63 ± 9.020.93 ± 7.39

Adverse events

Collected over From baseline (week 0) to the end of study (week 45). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
INSULIN GLARGINE (REDUCED) + SEMAGLUTIDE1/288 (0.3%)17/288 (5.9%)92/288 (31.9%)
INSULIN GLARGINE (TITRATED)1/284 (0.4%)15/284 (5.3%)13/284 (4.6%)
Most frequent serious events
Showing 10 of 40
Most frequent serious events
EventINSULIN GLARGINE (REDUCED) + SEMAGLUTIDEINSULIN GLARGINE (TITRATED)
Atrial fibrillationCardiac disorders0/2882/284
Chest painGeneral disorders2/2880/284
Acute myocardial infarctionCardiac disorders1/2881/284
AnaemiaBlood and lymphatic system disorders0/2881/284
Aortic dissectionVascular disorders0/2881/284
Cardiac failureCardiac disorders0/2881/284
Confusional statePsychiatric disorders0/2881/284
Gallbladder disorderHepatobiliary disorders0/2881/284
Humerus fractureInjury, poisoning and procedural complications0/2881/284
HyperglycaemiaMetabolism and nutrition disorders0/2881/284
Most frequent other events
Most frequent other events
EventINSULIN GLARGINE (REDUCED) + SEMAGLUTIDEINSULIN GLARGINE (TITRATED)
NauseaGastrointestinal disorders53/2882/284
DiarrhoeaGastrointestinal disorders39/28812/284
VomitingGastrointestinal disorders28/2881/284
ConstipationGastrointestinal disorders23/2880/284
Decreased appetiteMetabolism and nutrition disorders21/2882/284

Baseline characteristics

FAS included all randomized participants and were analysed according to the planned intervention.

Age, Continuous
Age, Continuous(Years)Insuline Glargine U100 (Reduced) + SemaglutideInsuline Glargine U100 (Titrated)Total
Mean61.7 ± 9.760.5 ± 10.361.1 ± 10.0
Sex: Female, Male
Sex: Female, Male(Participants)Insuline Glargine U100 (Reduced) + SemaglutideInsuline Glargine U100 (Titrated)Total
Female124129253
Male164156320
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Insuline Glargine U100 (Reduced) + SemaglutideInsuline Glargine U100 (Titrated)Total
Hispanic or Latino273158
Not Hispanic or Latino261254515
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Insuline Glargine U100 (Reduced) + SemaglutideInsuline Glargine U100 (Titrated)Total
American Indian or Alaska Native000
Asian332255
Native Hawaiian or Other Pacific Islander101
Black or African American10919
White243253496
More than one race101
Unknown or Not Reported011
08

Study locations

239 sites
  • Shoals Primary Care
    Sheffield, Alabama 35660, United States
  • Lenzmeier Fam Med CCT Research
    Glendale, Arizona 85308, United States
  • Synexus Clinical Research US, Inc./Desert Clinical Research,
    Mesa, Arizona 85213, United States
  • OneLife Direct Care Inc.
    Searcy, Arkansas 72143, United States
  • Unity Health-Searcy Medical Center
    Searcy, Arkansas 72143, United States
  • San Fernando Valley Hlth Inst, LLC
    Canoga Park, California 91304, United States
  • Velocity Clin Res-Chula Vista
    Chula Vista, California 91911, United States
  • John Muir Physicians Network
    Concord, California 94520, United States
  • Valley Research
    Fresno, California 93720, United States
  • Ascada Research
    Fullerton, California 92835, United States
  • Providence Medical Foundation
    Fullerton, California 92835, United States
  • Velocity Clinical Research Huntington Park
    Huntington Park, California 90255, United States
  • Scripps Memorial Hospital La Jolla
    La Jolla, California 92037, United States
  • Velocity Clin Res San Diego
    La Mesa, California 91942, United States
  • First Valley Medical Group
    Lancaster, California 93534, United States
  • Loma Linda Univ Hlth Cr Endo
    Loma Linda, California 92354, United States
  • Torrance Clin Res Inst, Inc.
    Lomita, California 90717, United States
  • NRC Research Institute
    Los Angeles, California 90015, United States
  • Downtown LA Res Ctr. Inc.
    Los Angeles, California 90017, United States
  • Velocity Clin Res Los Angeles
    Los Angeles, California 90017, United States
  • Valley Clinical Trials, Inc.
    Northridge, California 91325, United States
  • San Diego Family Care_San Diego
    San Diego, California 92111, United States
  • Wetlin Research Associates, Inc.
    San Diego, California 92120, United States
  • University Clin Investigators
    Tustin, California 92780, United States
  • Velocity Clin Res, Denver
    Denver, Colorado 80209, United States
  • Chase Medical Research LLC
    Waterbury, Connecticut 06708, United States
  • Indago Research & Health Center Inc.
    Hialeah, Florida 33012, United States
  • Encore Medical Research LLC
    Hollywood, Florida 33024, United States
  • Northeast Res Inst. Inc.
    Jacksonville, Florida 32204, United States
  • Jacksonville Ctr For Clin Res
    Jacksonville, Florida 32216, United States
  • Care-Partners-Clinical-Research, LLC
    Jacksonville, Florida 32277, United States
  • Suncoast Research Group, LLC
    Miami, Florida 33135, United States
  • New Horizon Research Center
    Miami, Florida 33165, United States
  • Elite Research Center
    Miami, Florida 33169, United States
  • Diverse Clinical Research Miami
    Miami, Florida 33175, United States
  • Reyes Clinical Research, Inc
    Miami, Florida 33175, United States
  • International Research Associates, LLC_Miami
    Miami, Florida 33183, United States
  • South Broward Research LLC
    Miramar, Florida 33027, United States
  • Suncoast Clin Res Port Richey
    New Port Richey, Florida 34652, United States
  • Suncoast Clinical Research, Inc._New Port Richey
    New Port Richey, Florida 34652, United States
  • Renstar Medical Research
    Ocala, Florida 34470, United States
  • Clinical Research Trials of Florida
    Tampa, Florida 33607, United States
  • CVS Store Number: 7689
    Atlanta, Georgia 30329-4015, United States
  • East Coast Institute for Res
    Canton, Georgia 30114, United States
  • Coastal Heritage Clinical Research
    Hinesville, Georgia 31313, United States
  • East Coast Institute for Res
    Macon, Georgia 31210, United States
  • Endocrine Research Solutions
    Roswell, Georgia 30076, United States
  • CVS Store Number: 05520
    Savannah, Georgia 31405-6901, United States
  • Solaris Clinical Research
    Meridian, Idaho 83646, United States
  • Cedar-Crosse Research Center
    Chicago, Illinois 60607, United States
  • WellNow Urgent Care
    Chicago, Illinois 60661, United States
  • Brengle Family Medicine
    Indianapolis, Indiana 46260, United States
  • West Broadway Clinic
    Council Bluffs, Iowa 51501, United States
  • Iowa Diab & Endo Res Center
    West Des Moines, Iowa 50265, United States
  • Iowa Diab & Endo Res Center
    West Des Moines, Iowa 50266, United States
  • Cotton O'Neil Diab & Endo Ctr
    Topeka, Kansas 66606, United States
  • The Research Group of Lexington LLC
    Lexington, Kentucky 40503, United States
  • L-MARC Research Center
    Louisville, Kentucky 40213, United States
  • Arthritis And Diabetes Clinic, Inc.
    Monroe, Louisiana 71203, United States
  • AMR New Orleans
    New Orleans, Louisiana 70119, United States
  • Ileana J. Tandron, MD APMC (a private medical office)
    Slidell, Louisiana 70461, United States
  • MedStar Hlth Res Institute
    Hyattsville, Maryland 20782, United States
  • Endo And Metab Cons
    Rockville, Maryland 20852, United States
  • Brigham & Women's Hospital
    Boston, Massachusetts 02115, United States
  • Joslin Diabetes Center
    Boston, Massachusetts 02215, United States
  • Northern Pines Hlth Ctr, PC
    Buckley, Michigan 49620, United States
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
  • Elite Research Center
    Flint, Michigan 48532, United States
  • Arcturus HC PLC Troy Med Res
    Troy, Michigan 48098, United States
  • StudyMetrix Research LLC
    City of Saint Peters, Missouri 63303, United States
  • Mercury Str Med Grp, PLLC
    Butte, Montana 59701, United States
  • Clinical Research Advantage, Inc./Skyline Medical Center, PC
    Elkhorn, Nebraska 68022, United States
  • Methodist Physicians Clinic
    Fremont, Nebraska 68025, United States
  • Velocity Clin Res, Norfolk
    Norfolk, Nebraska 68701, United States
  • Midwest Regional Health Services
    Omaha, Nebraska 68144, United States
  • Univ of Nebraska Medical CTR
    Omaha, Nebraska 68198-3020, United States
  • Palm Research Center Inc-Vegas
    Las Vegas, Nevada 89128, United States
  • Southern New Hampshire Diabetes and Endocrinology
    Nashua, New Hampshire 03060, United States
  • Premier Research Inc.
    Trenton, New Jersey 08611, United States
  • AMC Community Endocrinology
    Albany, New York 12203, United States
  • Dr. Alexander Perkelvald
    Brooklyn, New York 11229, United States
  • Mid Hudson Med Res-New Windsor
    New Windsor, New York 12553, United States
  • Great Lakes Medical Research
    Westfield, New York 14787, United States
  • University of North Carolina Medical Center
    Chapel Hill, North Carolina 27514, United States
  • Physicians East Endocrinology
    Greenville, North Carolina 27834, United States
  • Carteret Medical Group
    Morehead City, North Carolina 28557, United States
  • Centricity Rsrch MHCity Multi
    Morehead City, North Carolina 28557, United States
  • Lillestol Research LLC
    Fargo, North Dakota 58104, United States
  • Velocity Clin Res Cleveland
    Beachwood, Ohio 44122, United States
  • Diab & Endo Assoc of Stark Co
    Canton, Ohio 44718, United States
  • Velocity Clin Res_Cincinnati
    Cincinnati, Ohio 45219, United States
  • Albert J Weisbrot
    Mason, Ohio 45040, United States
  • Advanced Med Res Maumee
    Maumee, Ohio 43537, United States
  • University of Toledo Medical Center
    Toledo, Ohio 43614, United States
  • University of Toledo_Toledo
    Toledo, Ohio 43614, United States
  • Intend Research
    Norman, Oklahoma 73069, United States
  • Lynn Institute of Norman
    Norman, Oklahoma 73069, United States
  • Velocity Clinical Res Medford
    Medford, Oregon 97504, United States
  • Heritage Valley Multispeciality Group Inc
    Beaver, Pennsylvania 15009, United States
  • Richard M Kastelic MD Assoc
    Johnstown, Pennsylvania 15905, United States

Showing the first 100 of 239 sites across 12 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2022 to primary completion in Mar 2025, 30 months.

Results were first posted in May 2026, 1 year 2 months after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 30 months is above that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2022
First posted
Aug 24, 2022
StartActual
Aug 29, 2022
Primary completionActual
Mar 5, 2025
CompletionActual
Apr 9, 2025
Results first posted
May 11, 2026
Last update
May 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05514535
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Aug 24, 2022
Start date
Aug 29, 2022
Primary completion
Mar 5, 2025
Completion
Apr 9, 2025
Results posted
May 11, 2026
Last update
May 11, 2026

Study contacts

Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Semaglutide

Start the discussion